Schwarz S, Schwab S, Steiner H H, Hanley D, Hacke W
Neurologische Klinik, Universität, Heidelberg.
Nervenarzt. 1999 Feb;70(2):123-30. doi: 10.1007/s001150050412.
Intraventricular administration of recombinant tissue plasminogen activator (rt-PA) is an experimental therapy to hasten the lysis of intraventricular hemorrhages. We report nine patients (7 male, 2 female, mean age 64a) with intracerebral hematoma with ventricular extension who were treated with intraventricular infusion of rt-PA (2-32 mg, mean dose 17 mg). In two patients, clinically significant bleeding complications were associated with the fibrinolytic therapy. In one of these patients, fibrinolytic therapy was stopped. Other complications could not be observed. In eight of all nine patients, a rapid and extensive reduction of the amount of intraventricular blood occurred. A persistent shunt became necessary in two patients. We conclude, that intraventricular fibrinolysis probably leads to a faster clearance of intraventricular blood. Despite of fibrinolytic treatment, a permanent shunt becomes necessary in some cases. Intraventricular fibrinolysis is a potentially hazardous therapy with the risks of bleeding complications and infection.
脑室内注射重组组织型纤溶酶原激活剂（rt-PA）是一种用于加速脑室内出血溶解的实验性疗法。我们报告了9例（7例男性，2例女性，平均年龄64岁）伴有脑室扩展的脑内血肿患者，他们接受了脑室内输注rt-PA治疗（剂量为2 - 32毫克，平均剂量17毫克）。2例患者出现了与纤溶治疗相关的具有临床意义的出血并发症。其中1例患者停止了纤溶治疗。未观察到其他并发症。在全部9例患者中的8例，脑室内血量迅速且大量减少。2例患者需要持续进行分流术。我们得出结论，脑室内纤溶可能会使脑室内血液清除得更快。尽管进行了纤溶治疗，但在某些情况下仍需要永久性分流术。脑室内纤溶是一种具有出血并发症和感染风险的潜在危险疗法。
